|
Apr 3
|
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
|
|
Apr 2
|
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
|
|
Mar 28
|
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
|
|
Mar 27
|
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
|
|
Mar 26
|
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 20
|
3 Nightmare Nasdaq Stocks Not Worth Holding Another Day
|
|
Mar 20
|
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
|
|
Mar 20
|
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
|
|
Mar 19
|
Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA
|
|
Mar 14
|
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
|
|
Mar 12
|
Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails
|
|
Mar 11
|
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
|
|
Mar 11
|
Novo Nordisk's (NVO) Wegovy Gets FDA Nod to Reduce Heart Risk
|
|
Dec 9
|
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting
|
|
Nov 7
|
FibroGen, Inc. (NASDAQ:FGEN) Q3 2023 Earnings Call Transcript
|
|
Nov 7
|
Q3 2023 FibroGen Inc Earnings Call
|
|
Nov 6
|
FibroGen Inc (FGEN) Reports 155% YoY Increase in Q3 2023 Net Revenue
|
|
Nov 6
|
FibroGen (FGEN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Nov 6
|
FibroGen Reports Third Quarter 2023 Financial Results
|
|
Aug 9
|
Is There An Opportunity With FibroGen, Inc.'s (NASDAQ:FGEN) 42% Undervaluation?
|